Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial.

Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial.

Kyoto University Substance (KUS) 121, an ATPase inhibitor of valosin-containing protein, is a novel neuroprotectant. We tested the safety and effectiveness of KUS121 in patients with acute central retinal artery occlusion (CRAO). We conducted an investigator-initiated, first-in-humans, phase 1/2 cli...

Full description

Bibliographic Details
Main Authors: Hanako Ohashi Ikeda, Yuki Muraoka, Masayuki Hata, Eriko Sumi, Takafumi Ikeda, Takayuki Nakagawa, Hiroyasu Abe, Harue Tada, Satoshi Morita, Akira Kakizuka, Nagahisa Yoshimura, Akitaka Tsujikawa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0229068

Internet

https://doi.org/10.1371/journal.pone.0229068

Similar Items